Deal Watch: Anticipated Shire/Baxalta Merger Steals Attention From J.P. Morgan
Executive Summary
Industry's leading deal-making stage shows continued focus on immuno-oncology, with activity by Merck, Novartis and AstraZeneca.
You may also be interested in...
AstraZeneca Bets Big On Moderna’s Preclinical Messenger RNA Technology
The struggling pharma pays $240 million upfront for an exclusive collaboration to discover, develop and commercialize mRNA drugs in the cardiovascular, metabolic, renal and oncology spaces.
Finding Value Left On The Shelf: Karuna Case Study
PureTech’s gamble to take an older Eli Lilly drug off the shelf to redevelop in a new indication paid off. The company aims to replicate this 'Karuna model' in the near future.
Podcast: NodThera On The Role Of The Brain In Driving Chronic Disease
Alan Watt, CEO of NodThera, a clinical-stage biotech developing brain-penetrant NLRP3 inflammasome inhibitors to treat chronic inflammatory diseases, talks to In Vivo about the company’s pipeline and recent data publication in the field of obesity.